Business Wire

CA-MULTEFIRE-ALLIANCE

Share
MulteFire Alliance (MFA) Simplifies Path to 5G Private Network Deployment for Enterprise

MFA (MulteFire® Alliance), an international organization dedicated to enabling industry verticals to deploy private cellular networks globally, today announced its expanded mission to enable 5G private networks in unlicensed, shared and locally licensed spectrum by providing guidance to enterprises seeking to deploy their own network.

Leveraging existing 3GPP 5G specifications, MFA will deliver Uni5G Technology Blueprints to industry verticals. These blueprints will help enterprises select and implement the key features from the 3GPP standards that are relevant to their specific deployment. MFA will also develop best practices and deployment guides, including industry resources on understanding all available spectrum options for 5G private networks. The first Uni5G Technology Blueprint will be available in Q4 2021.

According to a recent industry report by ABI Research , the total addressable market size for 5G and 4G/LTE private network equipment for Industry 4.0 use cases will reach ~$35B by 2030.

“MFA paved the way for industries to contemplate how they can deploy their own private network in unlicensed spectrum using MulteFire 4G/LTE-based cellular technology with high-performance, built-in security and mobility benefits,” said Mazen Chmaytelli, president, MFA. “Now through our expanded role in enabling 5G private networks, MFA will provide industry verticals with practical guidance on deployment that will meet their unique requirements and determine which spectrum option is right for their site.”

MFA provides a unique global PLMN ID for 5G and MulteFire private networks to industry verticals

MFA has been awarded a global Public Land Mobile Network (PLMN) ID by the ITU. MFA is planning to make this PLMN ID available to industry verticals. The PLMN ID is a series of numbers that identifies a specific network and ensures that only authorized devices connect to that network.

With access to a unique global PLMN ID number, industry verticals are able to deploy their own 5G private network in locally licensed spectrum or a MulteFire private network in unlicensed spectrum today.

MFA members and others under MFA authorization are able to bundle the PLMN ID with their network equipment, thus simplifying the deployment process for enterprises by eliminating the need for them to separately apply for a PLMN ID.

“Across all industry verticals, we’re witnessing a drive to increase control, reliability and security through deployment of private networks,” said Chmaytelli. “Enterprises can now leverage locally licensed spectrum using Uni5G technology, and later can use global unlicensed or shared spectrum when 5G NR-U solutions become available. Through our Uni5G Technology Blueprints and our unique global PLMN ID, MFA has simplified the path to 5G private networks and is helping to accelerate the ecosystem.”

To join the MFA, learn more about Uni5G or how to access PLMN ID numbers, or receive notifications on the Uni5G Technology Blueprint, visit www.mfa-tech.org .

Resources:

About the MFA

MFA (MulteFire Alliance) is an international organization that is championing the global industry adoption of private cellular networks using MFA-defined MulteFire specifications for LTE and Uni5G technology blueprints for 5G. With Uni5G or MulteFire, enterprises can efficiently deploy their own optimized, reliable and secure private network in unlicensed, shared or locally licensed spectrum. For more information, visit www.mfa-tech.org .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye